Stay updated with breaking news from Exact Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
If we are to achieve the clinical and economic benefits of primary care and care continuity, the implementation and evaluation of strategies that reward clinicians and patients are warranted.
Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fourteen analysts that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price objective among […]
Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) General Counsel James Herriott sold 415 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $25,522.50. Following the completion of the sale, the general counsel now directly owns 6,943 […]
Exact Sciences ( NASDAQ:EXAS ) Full Year 2023 Results Key Financial Results Revenue: US$2.50b (up 20% from FY 2022...
Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.